PRIORTECH LTD (PRTC)
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (ERS) Congress
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (ERS) Congress
📈 **POSITIVE** • Medium confidence analysis (77%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business